Davenport Anthony P, Harmar Anthony J
Clinical Pharmacology Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Br J Pharmacol. 2013 Oct;170(4):693-5. doi: 10.1111/bph.12339.
The award of the 2012 Nobel Prize in Chemistry to Robert Lefkowitz and Brian Kobilka for their work on the structure and function of GPCRs, spanning a period of more than 20 years from the cloning of the human β2 -adrenoceptor to determining the crystal structure of the same protein, has earned both researchers a much deserved place in the pantheon of major scientific discoveries. GPCRs comprise one of the largest families of proteins, controlling many major physiological processes and have been a major focus of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) since its inception in 1987. We report here recent efforts by the British Pharmacological Society and NC-IUPHAR to define the endogenous ligands of 'orphan' GPCRs and to place authoritative and accessible information about these crucial therapeutic targets online.
2012年诺贝尔化学奖授予罗伯特·莱夫科维茨和布莱恩·科比尔卡，以表彰他们在G蛋白偶联受体（GPCRs）结构与功能方面的研究工作。从克隆人类β2肾上腺素能受体到确定同一蛋白质的晶体结构，这项研究跨越了20多年的时间，这两位研究人员在重大科学发现的万神殿中赢得了当之无愧的一席之地。GPCRs是最大的蛋白质家族之一，控制着许多主要的生理过程，自1987年成立以来，一直是国际基础与临床药理学联合会受体命名与药物分类委员会（NC-IUPHAR）的主要关注焦点。我们在此报告英国药理学会和NC-IUPHAR最近为确定“孤儿”GPCRs的内源性配体，并在网上提供有关这些关键治疗靶点的权威且易于获取的信息所做的努力。
